📣 VC round data is live. Check it out!
- Public Comps
- Nuvectis Pharma
Nuvectis Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nuvectis Pharma and similar public comparables like Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical and more.
Nuvectis Pharma Overview
About Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Founded
2020
HQ

Employees
13
Website
Financials (LTM)
EV
$227M
Valuation Multiples
Start free trialNuvectis Pharma Financials
Nuvectis Pharma reported last 12-month revenue of - and negative EBITDA of ($28M).
In the same LTM period, Nuvectis Pharma generated - in gross profit, ($28M) in EBITDA losses, and had net loss of ($28M).
Revenue (LTM)
Nuvectis Pharma P&L
In the most recent fiscal year, Nuvectis Pharma reported revenue of - and EBITDA of ($28M).
Nuvectis Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Nuvectis Pharma Stock Performance
Nuvectis Pharma has current market cap of $253M, and enterprise value of $227M.
Market Cap Evolution
Nuvectis Pharma's stock price is $9.52.
Nuvectis Pharma share price decreased by 2.7% in the last 30 days, and increased by 45.6% in the last year.
Nuvectis Pharma has an EPS (earnings per share) of $-1.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $227M | $253M | -2.3% | -2.7% | 23.2% | 45.6% | $-1.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNuvectis Pharma Valuation Multiples
Nuvectis Pharma trades at (8.1x) EV/EBITDA.
EV / Revenue (LTM)
Nuvectis Pharma Financial Valuation Multiples
As of June 3, 2026, Nuvectis Pharma has market cap of $253M and EV of $227M.
Nuvectis Pharma has a P/E ratio of (9.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nuvectis Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nuvectis Pharma Margins & Growth Rates
Nuvectis Pharma grew EBITDA by 4% in the last fiscal year.
Nuvectis Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Nuvectis Pharma Operational KPIs
Nuvectis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Nuvectis Pharma Competitors
Nuvectis Pharma competitors include Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical, Macrogenics, Entrada Therapeutics, Anavex Life Sciences, AFT Pharmaceuticals, Tetratherix and Sensorion.
Most Nuvectis Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.6x | 0.6x | 6.4x | - | |||
| 42025.8x | - | - | - | |||
| 0.9x | 0.9x | 9.3x | 9.6x | |||
| 3.6x | - | 25.6x | - | |||
| 0.9x | 1.0x | (2.3x) | - | |||
| 8.9x | 9.9x | (1.5x) | (1.4x) | |||
| - | - | (2.7x) | - | |||
| 1.8x | 1.8x | 16.6x | 15.9x | |||
This data is available for Pro users. Sign up to see all Nuvectis Pharma competitors and their valuation data. Start Free Trial | ||||||
Nuvectis Pharma VC Funding History
Before going public, Nuvectis Pharma raised $15M in total equity funding, across 1 round.
Nuvectis Pharma Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nuvectis Pharma
| When was Nuvectis Pharma founded? | Nuvectis Pharma was founded in 2020. |
| Where is Nuvectis Pharma headquartered? | Nuvectis Pharma is headquartered in United States. |
| How many employees does Nuvectis Pharma have? | As of today, Nuvectis Pharma has over 13 employees. |
| Who is the CEO of Nuvectis Pharma? | Nuvectis Pharma's CEO is Ron Bentsur. |
| Is Nuvectis Pharma publicly listed? | Yes, Nuvectis Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Nuvectis Pharma? | Nuvectis Pharma trades under NVCT ticker. |
| When did Nuvectis Pharma go public? | Nuvectis Pharma went public in 2022. |
| Who are competitors of Nuvectis Pharma? | Nuvectis Pharma main competitors include Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical, Macrogenics, Entrada Therapeutics, Anavex Life Sciences, AFT Pharmaceuticals, Tetratherix, Sensorion. |
| What is the current market cap of Nuvectis Pharma? | Nuvectis Pharma's current market cap is $253M. |
| Is Nuvectis Pharma profitable? | No, Nuvectis Pharma is not profitable. |
| What is the current EBITDA of Nuvectis Pharma? | Nuvectis Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Nuvectis Pharma? | Current EBITDA multiple of Nuvectis Pharma is (8.1x). |
| How many companies Nuvectis Pharma has acquired to date? | Nuvectis Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Nuvectis Pharma has invested to date? | Nuvectis Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Nuvectis Pharma
Lists including Nuvectis Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.